The Latest
-
Spencer Platt via Getty Images
Q&ABriOri BioTech sets the stage for the comeback of Vioxx
With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.
-
iStock via Getty Images
After 40 years, researchers discover new frontiers in the fight against HIV
Medical advances in the last two decades may now provide scientists with the right toolbox to target the long-elusive virus.
-
Stock via Getty Images
Are digital DCTs the answer for rare diseases?
How data from EHRs is helping to identify, diagnose and recruit patients to decentralized clinical trials.
-
Sophia Sharp-Donaldson, executive director, Global Strategic Sourcing and Procurement, Kite Pharma and one of this year's HBA Luminary honorees.
OpinionWhy 'soft' skills matter in the new era of leadership
Standout leaders honored by the Healthcare Businesswomen's Association discuss the rising value of the interpersonal approach.
-
Stock via Getty Images
In the hot pharma talent market, execs battle these recruitment misconceptions
One of the top recruiting firms in life sciences weighs in on how companies can attract the next wave of rising stars.
-
Permission granted by TauRx
ProfileWith the shine of amyloid fading, tau is a rising star in Alzheimer's
The tau theory in Alzheimer's is being put to the test with phase 3 trial results due later this month from TauRx Pharmaceuticals.
-
iStock via Getty Images
It's time to acknowledge access as a prescribing barrier
A new survey reveals how red tape limits patient access to doctor-preferred specialty drugs.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: AiCure's Michelle Marlborough
As chief product officer at AiCure, Michelle Marlborough is focused on solving tough patient challenges through technology.
-
Permission granted by Replimune/Philip Astley-Sparke
Where hope and uncertainty meet: A cutting-edge cancer developer's winding road
Replimune is on the precipice of a new kind of cancer treatment, but its CEO knows something about ambiguity.
-
Sarah Silbiger via Getty Images
FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have
New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.
-
Stock via Getty Images
Q&ABiotech Spotlight: Everest Medicines takes aim at unmet needs in Asia
With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.
-
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Ultra-sensitive tests bring biomarkers into the drug development forefront
An agreement between the biomarker assay maker Quanterix and pharma giant Eli Lilly could help discover new ways to treat Alzheimer's.
-
iStock via Getty Images
Pharma's solution to the digital advertising dilemma? Storytelling
Peter Shin, vice president of Client Services at Sonic Health, says quality storytelling, rather than trendy content, is central to a digital advertising strategy.
-
iStock via Getty Images
ProfileBreaking new ground: Longhorn's trailblazing effort to develop a universal flu vaccine
After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Amgen's Dr. Jane Parnes
As executive medical director, early development at Amgen, Dr. Jane Parnes has helped guide clinical research for upwards of 30 of the company’s investigational molecules, including the newly approved Tezspire for severe asthma — one of her career highlights.
-
Permission granted by Nelson Ambrogio.
ProfileBayer executive makes strides toward a finish line for rare cancers
Bayer's SVP and general manager of U.S. oncology completed the Boston Marathon to honor his brother and bring attention to rare cancers.
-
Stock via Getty Images
ProfileFrom cancer survivor to clinical trial innovator
How Alicia Staley is using her insights as a three-time cancer survivor to drive clinical trial improvements at Medidata.
-
Stock via Getty Images
A nuclear threat spurs France's Medesis to advance radiation therapy
In the event of a nuclear event — intentional or accidental — rapid and widespread deployment of effective treatments is paramount.
-
Stock via Getty Images
Q&AOne company's failed drug is this company's 'jewel'
Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.
-
doug4537 via Getty Images
The 'innovation gap' haunts Big Pharma, and the race is on for the next blockbusters
The next big innovation wave is out there, and as pharmas expect massive losses without enough internal R&D to fill those shoes, smaller biotechs beckon.
-
Permission granted by Alan Millar.
Q&AHow an open platform can shake up the drug development process
TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.
-
Permission granted by Laura Randa.
ProfileLaura Randa's aim to break down mental healthcare barriers for disabled patients
Despite the proliferation of mental health apps, many aren’t accessible for people with disabilities. The CEO of Toivoa plans to change that.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Gilead Science's Dr. Shanthi Ganeshan
As vice president of Global Regulatory Affairs, Oncology at Gilead, Ganeshan says there’s ‘never a dull moment’ in the quest to deliver therapies to patients.
-
D-Keine via Getty Images
ProfileMouse vs. machine: Using AI to solve the animal testing model in pharma
Quris is bringing its first drug tested preclinically using AI — rather than animal models — into human trials.
-
iStock via Getty Images
Q&AReal-world data is making drug development more true to life
How RWD is moving from the background to the spotlight in pharma’s development process.
